about
Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association studyCDK5RAP2 is required for spindle checkpoint functionAntitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesThe important molecular markers on chromosome 17 and their clinical impact in breast cancerBeyond taxanes: the next generation of microtubule-targeting agentsA role of WT1 in cell division and genomic stabilityExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerSmall molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.Lysophosphatidate induces chemo-resistance by releasing breast cancer cells from taxol-induced mitotic arrestSpindle poisons and cell fate: a tale of two pathways.Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpointDevelopment of a screen to identify selective small molecules active against patient-derived metastatic and chemoresistant breast cancer cellsTubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cellsPolymorphisms in the survivin promoter are associated with age of onset of ovarian cancerTargeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastropheSpecific kinesin expression profiles associated with taxane resistance in basal-like breast cancerBioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.Centrosomal Protein 70 Is a Mediator of Paclitaxel Sensitivity.Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cellsSulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma.Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cellsDrug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines.Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers.ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells.Taxane pathway.Preclinical profile of cabazitaxel.Expression and silencing of the microtubule-associated protein Tau in breast cancer cells.Reovirus cell entry requires functional microtubules.Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-β signallingTranscriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expressionDown-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia.
P2860
Q21261276-02B72487-3F59-42AF-9451-E064066E4A5FQ24321342-4952980B-98C1-4AF1-B450-DA869B9CB373Q24649780-F2CE614D-A59F-402D-BF63-DDEA5A25A1EBQ26774221-3FACCF71-12C1-4420-9461-3B4E0E510510Q26795445-3F89F149-0ECF-4576-B081-E39AFCF8DC74Q26796704-91FE01B2-F902-4596-8DCF-15249E9AFC60Q26859002-08CE51B5-005C-43ED-9FAD-CA696415E6B0Q26865369-1EA62EC6-E1A1-48DC-AB4D-5EB72D4C3164Q27009003-F16F218F-0E49-489E-B256-16D74EF7B41CQ28066481-1DB5726E-7C9B-4ECB-AD01-FA88FFD0F40BQ28261026-39D31AA7-E267-4903-A6D7-F7F09C9EE5E3Q28478339-44FC5945-46BD-4A5F-80DD-BA090D985AA8Q30431071-E1470B19-9394-47FE-9649-D6A1F7D28E98Q30560953-348B78BF-FDE1-4C54-8C28-308DE9994750Q31123725-7696A8A1-D877-4D45-8DE7-EE3900C13D1FQ33552792-FC843287-0F86-48BC-A1C8-C2D1FF60A306Q33572996-63787F45-4BC5-4B1C-8A94-82CC10946FD1Q33584823-0200A0A6-4C86-47E1-ADC4-438DE80E939FQ33684080-9E9563C7-43B2-4359-99BF-2647403A4396Q33818738-A02C2235-D0C3-4C5A-99C8-A9D7DEB4CEFFQ33827019-B805E5A5-3F74-433D-B141-5E892C2AB39FQ33838951-FFE30761-177E-4950-AF3A-AA424241F993Q33893910-90423800-C0BC-4F13-9366-53B915B330EEQ34048144-79BCDFAA-A106-4463-A7ED-27E7FA547D68Q34048154-F2C0D829-F818-489C-B379-273D8640B046Q34094167-8F6FB46B-0F11-419E-9C9A-B5A868D77CA3Q34103923-1C18C2ED-2C82-4D4C-B4A5-27DE50C44F61Q34104738-B90FF20E-CA98-4A14-B9C6-E7C16CAC4711Q34111215-5D3160BE-9D37-4B40-8421-228D5CB7CDDBQ34140986-E13243BC-28F4-4648-8180-411BC87011F6Q34154782-44510959-53BC-40F6-99FF-755136362EFCQ34375459-FBC27874-1300-41A4-AF69-B65284BEBAFAQ34390370-32286350-EF75-48B4-9872-F02DE4096781Q34394251-7EF1B6F2-703D-4499-A956-6FD01D9BFD04Q34726680-F7C04912-70E4-4FB2-8FA6-BD96E8CC1F3FQ34790998-86AA4908-687D-4E07-9E3D-41E7CBA7913AQ34998403-E9989FDF-260C-4CD4-BAC1-5040EAF425EDQ35067903-D93109E0-C187-4EB2-B5CF-32BB3D6E322EQ35154831-CC92A079-150B-4E8E-A080-FE4E9EA7BA25Q35377371-332901A0-5A59-4617-BE67-005529EE94DF
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Taxanes, microtubules and chemoresistant breast cancer.
@ast
Taxanes, microtubules and chemoresistant breast cancer.
@en
Taxanes, microtubules and chemoresistant breast cancer.
@nl
type
label
Taxanes, microtubules and chemoresistant breast cancer.
@ast
Taxanes, microtubules and chemoresistant breast cancer.
@en
Taxanes, microtubules and chemoresistant breast cancer.
@nl
prefLabel
Taxanes, microtubules and chemoresistant breast cancer.
@ast
Taxanes, microtubules and chemoresistant breast cancer.
@en
Taxanes, microtubules and chemoresistant breast cancer.
@nl
P2093
P1476
Taxanes, microtubules and chemoresistant breast cancer
@en
P2093
Barbara T McGrogan
Breege Gilmartin
Desmond N Carney
P304
P356
10.1016/J.BBCAN.2007.10.004
P407
P50
P577
2007-11-12T00:00:00Z